A pH/Enzyme-Sensitive Doxorubicin Prodrug Micelle for Safe and Effective Cancer Treatment
Molecules · 04.03.2026 · 31 (5) · 851
DOI: 10.3390/molecules31050851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 04.03.2026. Verfasst von Xiang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University, Beijing 100875, China. Hauptthemen laut MEDLINE: Doxorubicin, Micelles, Prodrugs, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Start-up Fund for Excellent Talents of Xuzhou Medical University, the National Natural Science Foundation of China, the Central Public Welfare Research Institutes.
Abstract (Originalsprache)
Objectives
This study developed pH/enzyme-sensitive polymeric HA-AAN-DOX (HAD) micelles to resolve the limited targeting specificity of chemotherapy drugs.
Methods
Hyaluronic acid (HA) and the chemotherapeutic agent doxorubicin (DOX) were conjugated via a hydrazone linkage utilizing an Ala-Ala-ASP tripeptide (AAN) as the connecting moiety, which is sensitive to the legumain enzyme. DOX was delivered via HAD micelles, which were activated by both hyaluronidase and the legumain enzyme. Key findings: The results revealed the remarkable antitumor efficacy of these micelles both in vivo and in vitro. Compared with that of doxorubicin hydrochloride (DOX·HCl), the incidence of toxic side effects was significantly reduced with the HAD micelle treatment. As a result, micelles composed of hyaluronic acid and doxorubicin (HAD) offer a reliable and effective method for drug delivery, with the potential to optimize the therapeutic impact of chemotherapeutic agents on tumors by reducing unintended side effects.
Conclusions
Micelles composed of hyaluronic acid and doxorubicin (HAD) offer a reliable and effective method for drug delivery, with the potential to optimize the therapeutic impact of chemotherapeutic agents on tumors by reducing unintended side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University, Beijing 100875, China.
- State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University College of Pharmacy, Yanji 133002, China.
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, China.
- Department of Pharmacy, Xuzhou Medical University, Xuzhou 221004, China.
Förderung
- the Start-up Fund for Excellent Talents of Xuzhou Medical University
- the National Natural Science Foundation of China
- the Central Public Welfare Research Institutes
- National Natural Science Foundation of China
- Start-Up Fund for Excellent Talents of Xuzhou Medical University
- Central Public Welfare Research Institutes
Zitieren
APA
Li, X., Wang, D., Wu, S., Na, N., Yang, X., Yi, D., Zhang, Z., Liang, Q., Zhao, Z., & Hua, Y. (2026). A pH/Enzyme-Sensitive Doxorubicin Prodrug Micelle for Safe and Effective Cancer Treatment. Molecules, 31(5), 851. https://doi.org/10.3390/molecules31050851
Vancouver
Li X, Wang D, Wu S, Na N, Yang X, Yi D, et al. A pH/Enzyme-Sensitive Doxorubicin Prodrug Micelle for Safe and Effective Cancer Treatment. Molecules. 2026;31(5):851. doi:10.3390/molecules31050851
BibTeX
@article{Li2026,
author = {Li, Xiang and Wang, Dan and Wu, Shengyue and Na, Na and Yang, Xue and Yi, Dongcheng and Zhang, Zixi and Liang, Qian and Zhao, Ziming and Hua, Yabing},
title = {A pH/Enzyme-Sensitive Doxorubicin Prodrug Micelle for Safe and Effective Cancer Treatment},
journal = {Molecules},
year = {2026},
volume = {31},
number = {5},
pages = {851},
doi = {10.3390/molecules31050851}
}
EUVIMED